Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Icu Medical (ICUI) Gross Profit (2016 - 2025)

Historic Gross Profit for Icu Medical (ICUI) over the last 17 years, with Q3 2025 value amounting to $200.9 million.

  • Icu Medical's Gross Profit fell 193.85% to $200.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $846.3 million, marking a year-over-year increase of 1003.8%. This contributed to the annual value of $824.8 million for FY2024, which is 1147.62% up from last year.
  • According to the latest figures from Q3 2025, Icu Medical's Gross Profit is $200.9 million, which was down 193.85% from $208.1 million recorded in Q2 2025.
  • In the past 5 years, Icu Medical's Gross Profit registered a high of $227.3 million during Q4 2024, and its lowest value of $112.7 million during Q1 2021.
  • Moreover, its 5-year median value for Gross Profit was $185.2 million (2024), whereas its average is $177.5 million.
  • Its Gross Profit has fluctuated over the past 5 years, first tumbled by 719.43% in 2021, then skyrocketed by 4982.87% in 2022.
  • Over the past 5 years, Icu Medical's Gross Profit (Quarter) stood at $127.5 million in 2021, then soared by 37.22% to $174.9 million in 2022, then dropped by 1.92% to $171.6 million in 2023, then skyrocketed by 32.45% to $227.3 million in 2024, then dropped by 11.61% to $200.9 million in 2025.
  • Its last three reported values are $200.9 million in Q3 2025, $208.1 million for Q2 2025, and $210.1 million during Q1 2025.